DTX3L is reported to regulate the ubiquitin modification of PARP family proteins (PARP1, PARP2, PARP9, PARP14), promoting proliferation, migration and chemotherapy resistance of lymphoma, glioma, and melanoma (16). This evidence concerns the gene PARP9 and central nervous system cancer.